Prognostic factors for transcatheter arterial chemoembolization in patients with hepatocellular carcinoma complicated by portal vein tumor thrombus
-
摘要:
目的评估肝细胞癌(HCC)合并门静脉癌栓患者经肝动脉化疗栓塞术(TACE)治疗后的效果及影响预后的因素。方法回顾性分析2006年1月-2010年12月第四军医大学西京医院收治的152例行TACE治疗的HCC合并门静脉癌栓患者的临床资料。观察TACE术后肝衰竭、上消化道大出血、栓塞后综合征等发生情况,分析生存期资料与影响预后的因素。Kaplan-Meier法计算累积生存率,采用Log-Rank法进行单因素分析,Cox比例风险模型进行多因素分析。结果患者中位生存时间为5.0(95%可信区间:4.45.6)个月,6、12、18个月的累积生存率分别为37%、18%和9%。单因素分析显示肿瘤大小、肿瘤类型、肝两叶累及、远处转移和Child-Pugh分级是HCC合并门静脉癌栓患者行TACE治疗预后的影响因素(χ2值分别为5.108、11.542、6.036、12.319、22.574,P值均<0.05);多因素分析显示肿瘤大小、肿瘤类型、远处转移和Child-Pugh分级是影响患者预后的独立危险因素(Wald值分别为11.243、5.021、7.651、25.876,P...
Abstract:Objective To investigate the therapeutic effect of transcatheter arterial chemoembolization( TACE) in patients with hepatocellular carcinoma( HCC) complicated by portal vein tumor thrombus,and to identify related prognostic factors. Methods The clinical data of152 HCC patients with portal vein tumor thrombus who were admitted to Xijing Hospital of Fourth Military Medical University and received TACE from January 2006 to December 2010 were analyzed retrospectively. The occurrence of post- TACE liver failure,upper gastrointestinal bleeding,and post- embolization syndrome was observed,and survival data and prognostic factors were analyzed. The Kaplan- Meier method was used to calculate cumulative survival rate,the log- rank test was used for univariate analysis,and the Cox proportional hazards model was used for multivariate analysis. Results The median survival time was 5. 0 months,and the 6-,12-,and 18- month cumulative survival rates were 37%,18%,and 9%,respectively. Univariate analysis showed that tumor size,tumor type,involvement of both liver lobes,distant metastasis,and Child- Pugh class were the prognostic factors for TACE in HCC patients with portal vein tumor thrombus( χ2= 5. 108,11. 542,6. 036,12. 319,and 22. 574,respectively,all P < 0. 05); multivariate analysis showed that tumor size,tumor type,distant metastasis,and Child- Pugh class were the independent prognostic factors( Wald values = 11. 243,5. 021,7. 651,and25. 876,respectively,all P < 0. 05); Child- Pugh class was the only influencing factor for liver failure in HCC patients with portal vein tumor thrombus( P = 0. 015). Conclusion TACE is safe and effective in HCC patients with portal vein thrombus and good liver function.Tumor size,tumor type,distant metastasis,and Child- Pugh class are the main factors influencing survival,which provides a basis for clinicians to select appropriate interventional therapies.
-
Key words:
- carcinoma,hepatocellular /
- portal vein /
- chemoembolization,therapeutic /
- prognosis /
- risk factors
-
[1]CHUNG JW,PARK JH,HAN JK,et al.Hepatocellular carcinoma and portal vein invasion:results of treatment with transcatheter oily chemoembolization[J].AJR Am J Roentgenol,1995,165(2):315-321. [2]IZUMI R,SHIMIZU K,LI T,et al.Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection[J].Gastroenterology,1994,106(3):720-727. [3]KUO YH,LU SN,CHEN CL,et al.Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis[J].Eur J Cancer,2010,46(4):744-751. [4]LAU WY,LAI EC,YU SC.Management of portal vein tumor thrombus[M]//LAU WY,Eds.Hepatocellular carcinoma.Singapore:World Scientific Publishing,2008:739-760. [5]LLOVET JM,REAL MI,MONTAA X,et al.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:a randomised controlled trial[J].Lancet,2002,359(9319):1734-1739. [6]LO CM,NGAN H,TSO WK,et al.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J].Hepatology,2002,35(5):1164-1171. [7]YAMADA R,SATO M,KAWABATA M,et al.Hepatic artery embolization in 120 patients with unresectable hepatoma[J].Radiology,1983,148(2):397-401. [8]KIM KM,KIM JH,PARK IS,et al.Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion[J].J Gastroenterol Hepatol,2009,24(5):806-814. [9]LUO J,GUO RP,LAI EC,et al.Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis:a prospective comparative study[J].Ann Surg Oncol,2011,18(2):413-420. [10]CHUNG GE,LEE JH,KIM HY,et al.Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival[J].Radiology,2011,258(2):627-634. [11]BRUIX J,SHERMAN M,American Association for the Study of Liver Diseases.Management of hepatocellular carcinoma:an update[J].Hepatology,2011,53(3):1020-1022. [12]SONG B,MIN P,OUDKERK M,et al.Cavernous transformation of the portal vein secondary to tumor thrombosis of hepatocellular carcinoma:spiral CT visualization of the collateral vessels[J].Abdom Imaging,2000,25(4):385-393. [13]PENTECOST MJ,DANIELS JR,TEITELBAUM GP,et al.Hepatic chemoembolization:safety with portal vein thrombosis[J].J Vasc Interv Radiol,1993,4(3):347-351. 期刊类型引用(11)
1. 肖春桃,李贤秋,甘佩灵,潘潇,周贤. 基于倾向性评分匹配分析门静脉血栓对肝硬化患者预后的影响. 临床肝胆病杂志. 2021(08): 1829-1835 . 本站查看
2. 王彤,牛焕章,杜廷伟,魏乐群. 乙型肝炎肝硬化患者门静脉血栓发生的影响因素及抗凝治疗效果研究. 深圳中西医结合杂志. 2021(17): 134-136 . 百度学术
3. 姜炅,袁佳,史海涛,戴社教. 血清ALT、AST联合NFS评分对非酒精性脂肪性肝硬化患者食管胃底静脉曲张严重程度的评估价值. 中西医结合肝病杂志. 2020(04): 314-317 . 百度学术
4. 李英,高磊,胡扬喜,胡德升. 低分子肝素钙联合右旋糖酐在肝硬化门静脉高压症术后静脉血栓形成预防中的应用. 肝脏. 2019(07): 788-790 . 百度学术
5. 吕靖,董思思,顾宏图,赵长青,刘成海. 肝硬化并发门静脉血栓的危险因素及中医证候特点. 临床肝胆病杂志. 2019(10): 2210-2213 . 本站查看
6. 陈仙艳. 肝硬化合并上消化道出血患者门静脉血栓形成危险因素分析与护理. 护理实践与研究. 2019(18): 13-15 . 百度学术
7. 牟思玉,杨哲,吴力群,邱轩,郭珈铭. 肝硬化门静脉高压脾切除术后门静脉血栓形成的预测因素分析. 临床肝胆病杂志. 2018(01): 106-111 . 本站查看
8. 张津瑜,陈文显,沈华,王雁,张国雷,慎华平,吴万波,魏云海. 大鼠门静脉系统血栓形成模型的建立和观察. 中国普通外科杂志. 2018(06): 724-731 . 百度学术
9. 邢文立,李谦. 重症监护病房肝病患者的血栓预防与出血控制. 临床肝胆病杂志. 2018(10): 2237-2240 . 本站查看
10. 李志州,向俊峰,周威,唐亮. 探讨门脉高压及外伤性脾破裂行脾切除术后血小板升高及门静脉血栓形成情况. 肝胆外科杂志. 2018(04): 280-282 . 百度学术
11. 王士浩,张宏伟. 肝硬化合并门静脉血栓形成危险因素的病例对照研究. 中国中西医结合消化杂志. 2017(11): 867-870 . 百度学术
其他类型引用(12)
-